Omnicell, Inc. reported $1.25B of revenue over the trailing twelve months, +8.5% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.25B (to Q2 2026). Net income: $39M, trailing twelve months to Q2 2026. Free cash flow: $143M, trailing twelve months to Q2 2026. Operating margin: 4.7%, trailing twelve months to Q2 2026.

OMCLOmnicell, Inc.

Healthcare

$35.81+14% 1Y

$35.81

$29.4652 weeks$51.39

OMCL as reported

Omnicell, Inc. reported $1.25B of revenue over the trailing twelve months, +8.5% on the year before. 11 reported series are charted on this page, each one as filed.

$1.25B

Revenue, trailing twelve months · to Q2 2026 · +8.5% against the twelve months before

Net income: $39M
Net income · +69% year on year · trailing twelve months to Q2 2026
Free cash flow: $143M
Free cash flow · +33% year on year · trailing twelve months to Q2 2026
Operating margin: 4.7%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for OMCL, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.25B	+8.5%	Q2 2026
Net income	$39M	+69%	Q2 2026
EPS	$0.84	+68%	Q2 2026
Gross margin	45%	n/a	Q2 2026
Operating margin	4.7%	n/a	Q2 2026
Net margin	3.1%	n/a	Q2 2026
ROE	1.6%	n/a	Q2 2026
ROA	1.0%	n/a	Q2 2026
ROIC	7.3%	n/a	Q2 2020 · 24 quarters behind
Free cash flow	$143M	+33%	Q2 2026
P/E	42.6	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.